Famprofazone, a major ingredient of Gewolen ® , is an analgesic that has been demonstrated to be metabolized to methamphetamine (MA) and amphetamine (AM) following administration. Therefore, a famprofazone user may be interpreted as an illicit MA abuser in Taiwan because the user's urine tested positive for MA. The purpose of this study was to investigate whether the concentration of MA metabolized from a single dose of Gewolen users would offend the official controlled substance regulation and be identified as MA-positive. Subjects (n = 6) received 25 mg of famprofazone and collected all urine specimens at certain timed intervals for 48 h after drug administration. The urine specimens were screened by immunoassay and then confirmed by gas chromatography-mass spectrometry (GC-MS). The highest concentration of amphetamines by immunoassay was 1954 ng/mL, and 18.8% of the urine specimens' amphetamines concentrations exceeded 500 ng/mL. The MA and AM concentrations by GC-MS analysis of these urine specimens ranged from 901 to 2670 ng/mL and 208 to 711 ng/mL, respectively. These urine specimens were interpreted as MApositive (≥ ≥ 500 ng/mL MA and ≥ ≥ 100 ng/mL AM), according to the official test methods of Taiwan. The MA positive results appeared within 2-34 h. It is therefore clearly possible to misinterpret the legitimate famprofazone user as an MA abuser in Taiwan.
Introduction
Famprofazone (3-[N-methyl-(α-methyl-β-phenyl)-ethylaminomethyl]-4-isopropylnorantipyrine) is an analgesic that has been demonstrated to be metabolized to methamphetamine (MA) and amphetamine (AM) following administration (1, 2) . After administration of racemic famprofazone, the R-(2)-forms of MA and AM are excreted in urine (2) . MA (R,S-N-methyl-1-phenyl-2-propanamine) and AM (R,S-1-phenyl-2-propanamine) are powerful stimulants of the central nervous system. They are used as legitimate medicaments, drugs of abuse, or doping agents in sports (2) . After MA use, both MA and AM are excreted in the urine (3) . Therefore, the detection of urinary MA and AM in forensic analysis can be an indicator of illicit MA abuse. However, an MA-positive result may be caused by famprofazone administration.
Two legally and locally manufactured brand-name medicines (Gewolen tablet and Paisao ® capsule) containing fampro fazone are found on the market. Each Gewolen tablet (433 mg) contains 25 mg of famprofazone, 200 mg of acetaminophen, 75 mg of isopropyphenazone, and 25 mg of caffeine. Each Paisao capsule contains 25 mg of famprofazone, 250 mg of acetaminophen, 75 mg of isopropyphenazone, and 30 mg of caffeine anhydrous. Both drugs are used for pain relief, and the recommended Gewolen usage for an adult is one tablet (25 mg of famprofazone) per dose and twice per day (4) . Studies showed that after the administration of 50 mg of famprofazone, the urinary concentrations of MA and AM exceeded 500 ng/mL and 100 ng/mL, respectively (5) (6) (7) (8) .
MA and AM, both strong central nervous system stimulants, are classified as a Schedule 2 drug under the Controlled Drugs Act and are listed as restricted ingredients that cannot be manufactured or traded in Taiwan (9) . MA and AM are considered illicit drugs in most of the drug-abuse urine-testing laboratories in Taiwan. Current practice requires the use of two assays based on different analytical principles. First, immunoassays are frequently used for urine screening in order to differentiate between negative and presumptively positive samples. Presumptively positive results (amphetamines screen ≥ 500 ng/mL) must be confirmed by a second independent method, such as gas chromatography-mass spectrometry (GC-MS). For the official "truly positive" MA test, the Food and Drug Administration (FDA) in Taiwan instructed its certified drug-abuse urine-testing laboratories that at least 100 ng/mL of AM must be present in urine specimens that are positive for MA ≥ 500 ng/mL (10) . Therefore, distinguishing the differences in MA and AM in urine between famprofazone users and MA abusers is an important issue (11) .
The d-isomer of MA is a serious illicit drug because it is more potent in psychostimulating activities than l-isomers (12) . Chan et al. (13) demonstrated that the urinary d-enantiomers of MA and AM from MA abusers in Taiwan were 97.5 ± 1.7% and 98.6 ± 2.1%, respectively. Furthermore, the MA and AM metabolized from famprofazone are both the d-and the lenantiomers. Studies showed that 70-100% of l-MA and 50-73% of l-AM were presented in urine after famprofazone administration (6, 7, 14) . Detection of the enantiomeric composition of MA and AM is very valuable in determining the involvement of this drug. Famprofazone is also converted to several other metabolites, including 3-hydroxymethylpyrazolone, which is subsequently excreted in the urine (15) . One study (1) suggested that detection of 3-hydroxymethylpyrazolone or other components together with the concentrations and enantiomeric composition of the MA and AM in the sample allows the determination of the use of famprofazone.
From a forensic standpoint, it is important to consider that the precursor drugs are controlled and dispensed by prescription. Unfortunately, Gewolen and Paisao can be purchased in drugstores without a prescription, and thus Gewolen and Paisao users may lack valid medical prescriptions to help explain the MA-positive urinary result. Moreover, there are no Medical Review Officers to review laboratory results and determine the possibility of valid medical use of the drug in Taiwan. Although the enantiomeric composition of MA and AM is a useful method, the detection of enantiomers is not a routine test in Taiwan. Therefore, a famprofazone user may be interpreted as an illicit MA abuser because he or she tested positive for both MA and AM.
Several studies have investigated the urinary concentrations of MA after administering 50 mg of famprofazone (5) (6) (7) (8) 14 MA). Other chemicals were purchased from Merck (Darmstadt, Germany).
Materials and Methods

Chemicals and reagents
Drug administration and urine collection
Six untrained healthy volunteers (1 female and 5 males) with a mean age (± SD) of 25.2 (± 1.9) years, height of 174.5 (± 7.7) cm, and body mass of 79.0 (± 14.1) kg participated in the experiment. Subjects administered one tablet of Gewolen with 200 mL of water 30 min after breakfast. Urine specimens were collected in polyethylene bottles in the intervals of 0-1, 1-2, 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-12, 12-15, 15-22, 22-28, 28-34, 34-40, and 40-48 h after administering the drug. To ensure sufficient urine flow during the sampling period, 100 mL of water was ingested at 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, and 15 h on treatment day. The pH, volume, and specific gravity of each urine specimen at room temperature were recorded, and the specimen was stored at -20°C before sample preparations for screening and chromatographic analysis. Approval for the study's procedures was granted by the Committee for Research on Human Subjects of Da Yeh University.
Analytical procedure for MA and AM
Two hundred microliters of urine specimens were used to screen the amphetamines by a HITACHI-7600 automatic screening analyzer (Tokyo, Japan) and DRI ® amphetamines immunoassay reagents (Microgenic, Fremont, CA) kits. After the screening, the urine specimens were then analyzed by GC-MS with solid-phase extraction (SPE) to confirm the concentrations of MA and AM. Fifty microliters of MA-d 11 (5 µg/mL), 50 µL of AM-d 5 (5 µg/mL), and 1 mL of 100 mM phosphate buffer solution (pH 6.0) were added to 0.5 mL of the urine specimens. The sample solution was passed through a HCX SPE cartridge (130 mg, 3 mL) as described by Internal Sorbent Technology (Hengoed, U.K.). MA and AM were eluted with 3 mL of CH 2 Cl 2 /IPA/NH 4 OH (78:20:2, v/v/v). The extraction solution was evaporated to dryness under a gentle stream of nitrogen gas at room temperature. The residue was added to 100 µL of ethyl acetate and 25 µL of HFBA and incubated for 20 min at 70°C. A blank urine specimen was collected from a non-drug user. None of the drug in urine was detected by full-scan GC-MS. The blank human urine was spiked with MA and AM at the concentrations of 15.625, 31.25, 62.5, 125, 250, 500, 1000, and 2000 ng/mL for quantitative comparisons. Other quality control samples (250, 500, and 750 ng/mL) were prepared in the same way for precision evaluation.
Pharmacokinetic parameters for MA and AM were calculated. The time to reach maximum concentration (T max ) and maximum urinary excretion rate [(dXu/dt) max ] were directly determined from the resulting concentration-time profiles. The elimination rate constant was calculated from log-linear leastsquares regression of the terminal phase data points. The terminal elimination half-life (t ½ ) was calculated as 0.693 divided by the elimination rate constant. Non-compartmental model was applied to calculate the area under the urine concentration-time curve from 0 to 48 h (AUC 0-48 ), which was determined by the linear trapezoidal rule. The program used for the determination of these pharmacokinetic parameters was Kinetica software version 5.0 (ThermoFisher Scientific, Waltham, MA).
Analytical procedure for d-and l-MA and d-and l-AM
A GC-MS method described by Green- 
Results and Discussion
Reliability of the method Figure 1 illustrates the chromatogram obtained from drug-free urine spiked with both MA and AM at a final concentration of 250 ng/mL. The retention times of AM-d 5 , AM, MA-d 11 , and MA were 6.38, 6.40, 7.05, and 7.08 min, respectively. The linearity of the assay over the range of 15.625-2000 ng/mL showed correlation coefficients of r 2 = 0.9998 and 0.9999 for MA and AM, respectively. The limits of quantification and detection were 15.625 ng/mL. The intraday precision and accuracy obtained at three concentration levels (250, 500, and 750 ng/mL) were 0.73-1.62% and -11.30-19.78%, respectively. The interday precision and accuracy were 0.94-1.33% and -12.16-17.67%, respectively. These results demonstrated that this GC-MS method was suitable for the quantification of MA and AM in urine with satisfactory accuracy and precision. Figure 2 illustrates the chromatogram obtained from drug-free urine spiked with d-and l-enantiomers of MA and AM at a final concentration of 250 ng/mL. The retention times of l-AM-d 5 Table I illustrates the urinary pH, immunoassay, and GC-MS concentration as well as l-enantiomer composition of MA and AM after the administration of 25 mg famprofazone. The pH value of the urine specimens ranged from 5.23 to 7.46. The composition of l-MA and l-AM were 71.43 ± 3.81% (mean ± SD) and 56.21 ± 2.99%, respectively. This result is consistent with previous single-dose (6, 7) and multiple-dose studies (14) . The highest concentration of amphetamines was 1954 ng/mL, which appeared 5-6 h after administration. However, the amphetamines' concentrations in most of the urine specimens were lower than 1000 ng/mL. Screening by immunoassay within 48 h after famprofazone administration showed that 18.8% (18 out of 96) of the urine specimens' amphetamines concentrations exceeded the cutoff value (500 ng/mL), which ranged from 510 to 1954 ng/mL. The MA and AM concentrations [mean ± SD (range)] analyzed by GC-MS of these urine specimens were 1425 ± 555 (901-2760) ng/mL and 354 ± 117 (208-711) ng/mL, respectively. Data showed that all of these urine specimens were confirmed ≥ 500 ng/mL MA and ≥ 100 ng/mL AM. Thus, the 18.8% urine specimens will be considered as illicit MA abuse. The result of our study did not agree with Yoo et al. (8) , whose data showed that the positive result of EMIT would not be confirmed by GC-MS. This may be due to the differences of dosage administration and/or immunoassay kits. After one tablet of Gewolen administration, MA-positive results appearing at 2 to 34 h varied with different individuals (Table I) . Nevertheless, the average concentrations of MA and AM from 6 subjects demonstrated that MA-positive results appearing between 2 and 8 and 12 and 28 h after administration (Figure 3) . Studies of Oyler et al. (16) showed the peak MA and AM concentrations [mean ± SD (range)] after 10 mg MA administration were 2310-14,660 (4720 ± 2302) ng/mL and 264-660 ng/mL, respectively. This study showed that the MA concentrations in urine after the administration of 25 mg famprofazone were far lower than those concentrations in the urine of 10 mg MA users, but the AM concentration was similar. Evaluating the concentration of MA in the urine can also be very informative.
Urine analysis of the famprofazone users
Mean T max for both MA and AM was 5.7 ± 4.4 h (mean ± SD) (Table II) . Estimated (dXu/dt) max were 131.7 ± 26.2 µg/h in MA and 32.2 ± 6.1 µg/h in AM, respectively. Mean t ½ for MA and AM were 10.8 ± 2.8 h and 11.8 ± 4.2 h, respectively. Mean AUC 0-48 was 1515.3 ± 86.6 µg/mL·h in MA and 423.9 ± 64.2 µg/mL·h in AM, respectively. Data showed that the individuals had a great variation in the time of amphetamines metabolite excretion after 25 mg of famprofazone administration. Kim et al. (17) investigated the urinary pharmacokinetics of MA and AM following 10 mg and/or 20 mg MA oral administration. The mean MA t ½ for 10 and 20 mg MA oral administration was 22.6 ± 7.2 h (range 15.3-34.9 h) and 25.1 ± 6.0 h (range 20.1-32.7 h), respectively. Meanwhile, the mean AM t 1⁄2 for 10 and 20 mg MA oral administration was 19.8 ± 7.3 h (range 12.3-30.7 h) and 22.0 ± 8.0 h (range 13.6-31.5 h), respectively. The work by Oyler et al. (16) also showed the peak MA and AM concentrations after 10 mg MA administration occurring within 1.5-60 h. Therefore, the elimination half-life and T max of MA and AM after 25 mg famprofazone administration were shorter than in those of MA users.
The results indicated that the administration of one tablet of Gewolen definitely produced an MA-positive results under the official test methods of Taiwan. Oh et al. (19) indicated that at least 20% dose of famprofazone would break down to MA in the plasma, which could have significant clinical implications. The medication of famprofazone has been banned in Korea (8) , and it is also listed as a banned substance under the class of stimulant by the World Anti-Doping Agency (WADA) to prohibit athletes using it in competition since 2005 (18) . The Department of Health in Taiwan should consider withdrawing the medication of famprofazone.
Conclusions
This study investigated the metabolite results of ampheta mines, MA and AM, following the administration of 25 mg of famprofazone as well as interpreted the results according to the forensic rule of Taiwan. The results showed that 18.8% of the urine specimens within 48 h after 25 mg of famprofazone administration presented the amphetamines-positive result through immunoassay (≥ 500 ng/mL). The MA and AM concentrations of these urine specimens were confirmed ≥ 500 ng/mL MA and ≥ 100 ng/mL AM by GC-MS analysis. Thus, the administration of one tablet of Gewolen would result in misinterpretation of illicit MA abuse, according to the official analytical methods in Taiwan.
